Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H McCabe

Showing results (201-210 of 259) with videos related to

Pageof 26
Sort By:
The Lancet. Neurology|September 1, 2009
Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trialLeo H Bonati, Jörg Ederle, Dominick J H McCabe, et al.
Circulation|January 21, 1997
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trialC P Cannon, C H McCabe, C M Gibson, et al.
American Heart Journal|December 9, 2008
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromesChristopher P Cannon, Robert P Giugliano, Michael A Blazing, et al.
The New England Journal of Medicine|March 11, 2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevationMarc S Sabatine, Christopher P Cannon, C Michael Gibson, et al.
Circulation|November 18, 2005
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 TrialMarc S Sabatine, David A Morrow, Gilles Montalescot, et al.
Critical Pathways in Cardiology|March 15, 2008
Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 RegistryChristopher P Cannon, Maria Cecilia Bahit, J Mark Haugland, et al.
Journal of Thrombosis and Thrombolysis|June 21, 2006
Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trialC Michael Gibson, Cafer Zorkun, Peter Molhoek, et al.
Stroke|July 12, 2018
Statin Pretreatment and Microembolic Signals in Large Artery AtherosclerosisApostolos Safouris, Aristeidis H Katsanos, Antonios Kerasnoudis, et al.
The American Journal of Cardiology|September 8, 2001
Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapyJ A de Lemos, D A Morrow, C M Gibson, et al.
Circulation|September 2, 2008
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38Stephen D Wiviott, Eugene Braunwald, Dominick J Angiolillo, et al.
Pageof 26

Showing results (201-210 of 259) with videos related to

Sort By:
Pageof 26
The Lancet. Neurology|September 1, 2009
Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trialLeo H Bonati, Jörg Ederle, Dominick J H McCabe, et al.
Circulation|January 21, 1997
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trialC P Cannon, C H McCabe, C M Gibson, et al.
American Heart Journal|December 9, 2008
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromesChristopher P Cannon, Robert P Giugliano, Michael A Blazing, et al.
The New England Journal of Medicine|March 11, 2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevationMarc S Sabatine, Christopher P Cannon, C Michael Gibson, et al.
Circulation|November 18, 2005
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 TrialMarc S Sabatine, David A Morrow, Gilles Montalescot, et al.
Critical Pathways in Cardiology|March 15, 2008
Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 RegistryChristopher P Cannon, Maria Cecilia Bahit, J Mark Haugland, et al.
Journal of Thrombosis and Thrombolysis|June 21, 2006
Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trialC Michael Gibson, Cafer Zorkun, Peter Molhoek, et al.
Stroke|July 12, 2018
Statin Pretreatment and Microembolic Signals in Large Artery AtherosclerosisApostolos Safouris, Aristeidis H Katsanos, Antonios Kerasnoudis, et al.
The American Journal of Cardiology|September 8, 2001
Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapyJ A de Lemos, D A Morrow, C M Gibson, et al.
Circulation|September 2, 2008
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38Stephen D Wiviott, Eugene Braunwald, Dominick J Angiolillo, et al.
Pageof 26